After nearly a month of adjustment, Hong Kong stocks ushered in a new round of rise. As of 10:40, China Southern HSCEI ETF (159954) rose more than 1.7%, E Fund CSI Technology 50 ETF (159747), Hengzhietf (513600), and Hengzheng BioTech ETF (159615) rose 1.5%. In terms of fund level, since June, Southbound funds have net bought RMB 70.133 billion, and net bought RMB 215.944 billion in the past three months. Since the beginning of the year, they have net bought RMB 329.626 billion, equivalent to 113.88% of the net purchase of RMB 289.450 billion for the whole year of 2022. Tianfeng's research report pointed out that horizontally, the Hong Kong stock market has been in a low position of global value after the deep adjustment in the early stage, and its valuation cost performance has been highlighted. Comparing with the global market, China's assets are still cost-effective at present.
港股迎来上涨，H股ETF(159954)、香港科技ETF(159747)、恒生指数ETF(513600)、恒生生物科技ETF(159615)涨超1.5%
Hong Kong stocks have experienced an increase, with China Southern HSCEI ETF (159954), E Fund CSI Technology 50 ETF (159747), HengzhiETF (513600), and Hengsheng Healthcare ETF (159615) rising by more than 1.5%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.